<DOC>
	<DOCNO>NCT00446784</DOCNO>
	<brief_summary>CE 224,535 develop treatment rheumatoid arthritis . The purpose study evaluate safety tolerability CE 224,535 4 week treatment subject rheumatoid arthritis already receive methotrexate</brief_summary>
	<brief_title>Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adults patient rheumatoid arthritis Patients receive stable weekly dos oral methotrexate ( 5 25 mg/week administer single dose ) minimum 28 day ( 4 weeks/4 dos ) History chronic infectious disease genitourinary , pulmonary sinus infection . Any current known malignancy history malignancy within previous 5 year Pregnant lactating woman ; woman childbearing potential unwilling unable use acceptable method birth control study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>